View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Clinical Trials Analysis
February 26, 2021

Europe accounts for 19.3% share of global clinical trial activity in 2020

Europe accounted for a 19.3% share of global clinical trials activity in 2020, a decrease of 6.3% compared with a 25.6% average over the last ten-years, according to GlobalData.

In Europe, single country studies held a 70.8% share for all clinical trials in 2020, compared with the ten-year average of 69.2%. Multinational trials accounted for a 29.2% share in 2020 against an average of 30.8% in the last ten years.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Industry sponsored trials outnumber non-industry sponsored trials in Europe

Industry sponsored trials held a 62.5% share of all the clinical trials in Europe in 2020, a rise over their ten-year average of 61.6%. Non-industry sponsored trials accounted for a 37.5% share in 2020, down from an average of 38.4% in the last ten years.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

2020 industry sponsored clinical trials in Europe – Top therapy areas

Oncology was the leading therapy area for industry sponsored clinical trials in Europe in 2020 with a 25.3% share, down from its ten-year average of 26.2%.

Infectious Disease held a 19.9% share in 2020, up from its ten-year average of 10.8%.

In the third place was Central Nervous System with a 12.0% share in 2020, down from its ten-year average of 14.1%. Respiratory recorded a 10.4% share in 2020, a rise over its ten-year average of 8.0%.

With a share of 8.1% in 2020, Cardiovascular witnessed a drop over its ten-year average of 8.3%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Non-industry sponsored clinical trials in Europe by top therapy areas

Infectious Disease was the leading therapy area for non-industry sponsored clinical trials in Europe in 2020 with a 31.6% share, up from a ten-year average of 9.7%.

In the second place was Central Nervous System with a 20.3% share in 2020, which represented a drop over a ten-year average of 24.5%.

With a share of 16.8% in 2020, Oncology witnessed a drop over its ten-year average of 18.6%. Respiratory held a 13.3% share in 2020, as against ten-year average of 4.9%.

Cardiovascular held a 10.9% share, which was down from ten-year average of 13.6%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

2020 clinical trials in Europe by phase

In terms of phases, Phase II trials led the industry sponsored clinical trials in Europe in 2020, with a share of 38.2%, marking a rise over a ten-year average of 35.9%.

Phase III trials stood next with a 26.2% share in 2020, which was even against a ten-year average of 26.3%.

In the third place was Phase I trials with a 25.7% share in 2020, up from its ten-year average of 22.6%.

Phase IV trials held an 9.9% share in 2020, with a 5.3% drop over its ten-year average of 15.2%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

 

For non-industry sponsored clinical trials in Europe, Phase II trials held a leading share of 50.0% in 2020, up from its ten-year average of 46.4%.

In the second place was Phase IV trials that held a 25.7% share in 2020 and saw a 6.9% drop over a ten-year average of 32.6%.

Phase III trials stood at 18.5% share, as against ten-year average of 14.6%.

Phase I trials held a 5.8% share in 2020, down from its ten-year average of 6.5%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

 

Methodology: The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena